首页> 美国卫生研究院文献>Chemical Science >Penetration depth tunable BODIPY derivatives for pH triggered enhanced photothermal/photodynamic synergistic therapy
【2h】

Penetration depth tunable BODIPY derivatives for pH triggered enhanced photothermal/photodynamic synergistic therapy

机译:用于pH的渗透深度可调BODIPY衍生物可触发增强的光热/光动力协同治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Improving the deep-tissue phototherapy (PDT) efficiency in the near-infrared (NIR) region has become one of the major challenges in clinics for cancer treatment. Developing intelligent photosensitizers (PSs) responding to tumor-specific signals sensitively to minimize side effects is another major challenge for tumor phototherapy. Herein, three phenyl-based boron dipyrromethene (BODIPY) compounds with different numbers of diethylaminophenyl groups introduced onto the BODIPY core have been designed and synthesized by the Knoevenagel condensation reaction. The absorbance of these compounds (BDPmPh, BDPbiPh, and BDPtriPh) can be controlled easily for realizing the tunable penetration depth. Moreover, the diethylamino groups in these designed PSs can serve as proton acceptors triggered by the low pH in lysosomes which can enhance the efficacy of photodynamic and photothermal therapy. The corresponding nanoparticles (NPs) of the compounds are prepared through a nanoprecipitation method and in vitro studies demonstrate that the ultra-low drug dosage of BDPtriPh NPs (half-maximal inhibitory concentration, IC50 = 4.16 μM) is much lower than that of BDPmPh NPs (50.09 μM) and BDPbiPh NPs (22.4 μM). In vivo fluorescence imaging shows that these NPs can be passively targeted to tumors by the enhanced permeability and retention (EPR) effect, and BDPtriPh NPs exhibit the fastest accumulation (about 4 hours). In vivo phototherapy indicates that BDPtriPh NPs with the longest NIR absorbance (813 nm) and highest photothermal conversion efficiency (60.5%) can effectively inhibit tumor growth and reduce side effects to normal tissues. This study provides a strategy to modulate the photoconversion characteristics of PSs for both penetration-depth-tunable and pH-dependent PDT/PTT synergistic cancer therapy in clinics.
机译:提高近红外(NIR)区域的深层组织光疗(PDT)效率已成为临床治疗癌症的主要挑战之一。开发灵敏地响应肿瘤特异性信号以最小化副作用的智能光敏剂(PSs)是肿瘤光疗的另一个主要挑战。在此,已经设计并通过Knoevenagel缩合反应合成了三种具有不同数量的二乙基氨基苯基的苯基基硼二吡咯亚甲基(BODIPY)化合物。可以轻松控制这些化合物(BDPmPh,BDPbiPh和BDPtriPh)的吸光度,以实现可调节的穿透深度。此外,这些设计的PS中的二乙氨基可作为溶酶体中低pH值触发的质子受体,从而增强光动力和光热疗法的功效。化合物的相应纳米颗粒(NPs)是通过纳米沉淀法制备的,并且体外研究表明BDPtriPh NPs的超低药物剂量(半最大抑制浓度,IC50 = 4.16μM)远低于BDPmPh NPs。 (50.09μM)和BDPbiPh NP(22.4μM)。体内荧光成像显示,这些NP可以通过增强的通透性和保留(EPR)效应被动地靶向肿瘤,而BDPtriPh NP表现出最快的积累(约4小时)。体内光疗表明,具有最长的近红外吸收(813 nm)和最高的光热转换效率(60.5%)的BDPtriPh NP可有效抑制肿瘤生长并减少对正常组织的副作用。这项研究提供了一种策略,可调节PS的光转换特性,以用于临床中的渗透深度可调和pH依赖性PDT / PTT协同癌症治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号